DK0500108T3 - Forbedret aktivering af rekombinante proteiner - Google Patents

Forbedret aktivering af rekombinante proteiner

Info

Publication number
DK0500108T3
DK0500108T3 DK92102864.3T DK92102864T DK0500108T3 DK 0500108 T3 DK0500108 T3 DK 0500108T3 DK 92102864 T DK92102864 T DK 92102864T DK 0500108 T3 DK0500108 T3 DK 0500108T3
Authority
DK
Denmark
Prior art keywords
recombinant proteins
enhanced activation
amino acids
helper sequences
relative hydrophobicities
Prior art date
Application number
DK92102864.3T
Other languages
English (en)
Inventor
Dorothea Dr Rer Nat Ambrosius
Carola Dr Rer Nat Dony
Rainer Dr Rer Nat Rudolph
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6425597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0500108(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Application granted granted Critical
Publication of DK0500108T3 publication Critical patent/DK0500108T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
DK92102864.3T 1991-02-21 1992-02-20 Forbedret aktivering af rekombinante proteiner DK0500108T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4105480A DE4105480A1 (de) 1991-02-21 1991-02-21 Verbesserte aktivierung von rekombinanten proteinen

Publications (1)

Publication Number Publication Date
DK0500108T3 true DK0500108T3 (da) 1997-03-24

Family

ID=6425597

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92102864.3T DK0500108T3 (da) 1991-02-21 1992-02-20 Forbedret aktivering af rekombinante proteiner

Country Status (20)

Country Link
US (1) US5578710A (da)
EP (1) EP0500108B1 (da)
JP (1) JP2528232B2 (da)
KR (1) KR950014493B1 (da)
AT (1) ATE144284T1 (da)
AU (1) AU641081B2 (da)
CA (1) CA2061569C (da)
CZ (1) CZ282744B6 (da)
DE (2) DE4105480A1 (da)
DK (1) DK0500108T3 (da)
ES (1) ES2093122T3 (da)
FI (1) FI106029B (da)
GR (1) GR3021395T3 (da)
HU (1) HU214881B (da)
IE (1) IE920276A1 (da)
IL (1) IL101024A (da)
MX (1) MX9200709A (da)
NO (1) NO300329B1 (da)
NZ (1) NZ241570A (da)
ZA (1) ZA921230B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
SE9301057L (sv) * 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
JP4799803B2 (ja) 2000-09-08 2011-10-26 マサチューセッツ インスティテュート オブ テクノロジー Ｇ−ｃｓｆアナログ組成物および方法
KR100899970B1 (ko) 2001-02-19 2009-05-28 메르크 파텐트 게엠베하 Ｔ-세포 에피토프의 동정 방법 및 감소된 면역원성을 갖는분자의 제조를 위한 용도
MXPA04000231A (es) 2001-07-11 2004-05-04 Maxygen Holdings Ltd Conjugados del factor de estimulacion de colonias de granulocitos.
KR100508358B1 (ko) 2002-03-20 2005-08-17 주식회사 바이오폴리메드 생체적합성 고분자가 시스테인 잔기에 화학양론적으로 결합된 ｇ-ｃｓｆ의 제조 방법
US7666627B2 (en) * 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
CA2586365A1 (en) 2004-11-05 2006-05-26 Northwestern University Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
BRPI0611221A2 (pt) 2005-06-01 2010-08-24 Maxygen Holdings Ltd polipeptÍdeos de g-csf peguilados e mÉtodos de produÇço dos mesmos
EP2049524A2 (en) * 2006-07-24 2009-04-22 Tetralogic Pharmaceuticals Corporation Iap inhibitors
CA2697265A1 (en) 2007-08-09 2009-02-19 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
US8758761B2 (en) 2007-09-30 2014-06-24 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
WO2011109556A2 (en) 2010-03-04 2011-09-09 Pfenex Inc. Method for producing soluble recombinant interferon protein without denaturing
EP2547699B1 (en) * 2010-03-17 2016-10-19 ratiopharm GmbH Method for obtaining biologically active recombinant human g-csf
PL2552949T3 (pl) 2010-04-01 2017-01-31 Pfenex Inc. Sposoby wytwarzania G-CSF w komórce gospodarza Pseudomonas
KR20150037959A (ko) * 2012-08-02 2015-04-08 에프. 호프만-라 로슈 아게 단량체 및 다량체 분자의 제조 방법 및 이의 용도

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4532207A (en) * 1982-03-19 1985-07-30 G. D. Searle & Co. Process for the preparation of polypeptides utilizing a charged amino acid polymer and exopeptidase
DK55685A (da) * 1985-02-07 1986-08-08 Nordisk Gentofte Enzym eller enzymkompleks med proteolytisk aktivitet
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US5082775A (en) * 1984-05-11 1992-01-21 Berlex Laboratories, Inc. Efficient process for isolating insoluble heterologous protein using non-ionic detergents
US4948729A (en) * 1985-03-25 1990-08-14 Cetus Corporation Production of soluble recombinant proteins
US4783415A (en) * 1985-03-28 1988-11-08 Meiji Seika Kabushiki Kaisha Gene coding for signal peptides and utilization thereof
US5087564A (en) * 1985-06-20 1992-02-11 Monsanto Company Release of recombinant peptides from polypeptides using V8 endopeptidase
DE3636903A1 (de) * 1985-12-21 1987-07-02 Hoechst Ag Fusionsproteine mit eukaryotischem ballastanteil
JPH0618781B2 (ja) * 1986-10-18 1994-03-16 中外製薬株式会社 感染症治療剤
US5013653A (en) * 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
JPH02500876A (ja) * 1987-03-20 1990-03-29 クリエイティブ・バイオマリキュールズ・インコーポレーテッド 組換えポリペプチドの製品およびその製造、単離および精製方法
AU1987088A (en) * 1987-06-24 1989-01-19 Novo Nordisk A/S A process for preparing a protein or polypeptide, a dna sequence coding for the polypeptide, a microorganism containing the dna sequence as well as the polypeptide and its use as a pharmaceutical preparation
DE3835350A1 (de) * 1988-10-17 1990-04-19 Boehringer Mannheim Gmbh Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
ZA901719B (en) * 1989-03-19 1991-01-30 Akzo Nv Hog cholera virus vaccine and diagnostics
US5191063A (en) * 1989-05-02 1993-03-02 University Of Medicine And Dentistry Of New Jersey Production of biologically active polypeptides by treatment with an exogenous peptide sequence
US5115102A (en) * 1989-07-21 1992-05-19 Monsanto Company Variant proteins and polypeptides possessing enhanced affinity for immobilized-metal affinity matrices
JPH06500084A (ja) * 1990-08-20 1994-01-06 ノボ　ノルディスク　アクティーゼルスカブ 生物学的に活性な化合物、その製造方法及びその利用

Also Published As

Publication number Publication date
IL101024A0 (en) 1992-11-15
EP0500108A3 (en) 1993-04-07
NO920671D0 (no) 1992-02-20
DE59207351D1 (de) 1996-11-21
KR950014493B1 (ko) 1995-12-02
EP0500108A2 (de) 1992-08-26
NO300329B1 (no) 1997-05-12
HU214881B (hu) 1998-07-28
IL101024A (en) 1996-06-18
ATE144284T1 (de) 1996-11-15
FI920742A (fi) 1992-08-22
FI920742A0 (fi) 1992-02-20
IE920276A1 (en) 1992-08-26
DE4105480A1 (de) 1992-08-27
HU9200548D0 (en) 1992-04-28
AU641081B2 (en) 1993-09-09
ZA921230B (en) 1992-11-25
NZ241570A (en) 1994-09-27
KR920016464A (ko) 1992-09-24
NO920671L (no) 1992-08-24
EP0500108B1 (de) 1996-10-16
FI106029B (fi) 2000-11-15
GR3021395T3 (en) 1997-01-31
CZ282744B6 (cs) 1997-09-17
CS49992A3 (en) 1992-09-16
US5578710A (en) 1996-11-26
ES2093122T3 (es) 1996-12-16
CA2061569A1 (en) 1992-08-22
MX9200709A (es) 1992-09-01
JPH05244977A (ja) 1993-09-24
JP2528232B2 (ja) 1996-08-28
AU1094892A (en) 1992-08-27
CA2061569C (en) 2000-10-24
HUT68021A (en) 1995-04-04

Similar Documents

Publication Publication Date Title
DK0500108T3 (da) Forbedret aktivering af rekombinante proteiner
DE69033040T2 (de) Verfahren zur Herstellung von biologisch aktivem Protein (z.B. TGF)
NO971875L (no) Cathepsin 02 protease
DE59101580D1 (de) Trägergebundene rekombinante proteine, verfahren zur herstellung und verwendung als immunogene und vakzine.
ATE255638T1 (de) Nukleotidsequenzen und gegen cycloheximid resistente proteine
DE68907635D1 (de) Loetmaterial fuer brillengestelle und brillengestelle, bei denen dieses loetmaterial verwendet ist.
TR199901190T2 (xx) Interferon-(alfa) N�kleik asitlerinin verilmesi ve sentezlenmesi i�in y�ntemler ve bile�imler.
DE59208622D1 (de) Dentalwerkstoffe auf Basis von (Meth)-Acrylaten
SE9602822D0 (sv) New receptor
DE68910771T2 (de) Verfahren zur Herstellung von verbessertem Proteinhydrolysat.
FI893587A (fi) Menetelmä ei-glykosyloidun rekombinantti-humaani-IL2:n valmistamiseksi sen pelkistyneessä muodossa
DK1040191T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
IT8719551A0 (it) Plasmidi ricombinanti utili perl'espressione in bacillus di proteine eterologhe.
DE59108261D1 (de) Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
DE69534738D1 (de) Leukocyten-aktivierender Faktor
ATE150765T1 (de) Neue peptide, deren intermediate, verfahren zu deren herstellung, antiallergische agenzien, vasodilatoren und immunoregulatoren
ATE76081T1 (de) Verfahren zur herstellung von dipeptiden mit nterminalen nichtproteinogenen aminosaeuren.